| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Methyl 5-hydroxypyridine-2-carboxylate does not have a defined biological target. It exhibits nitric oxide (NO) inhibitory effects in vitro. By inhibiting NO production, it may have potential anti-inflammatory activity. It is a phenolic acid found in Mahonia fortune.
|
|---|---|
| ln Vitro |
Tetrahydroxymethoxychalcone promotes the differentiation and proliferation of myoblasts[1].Compound 2, methyl 5-hydroxypyridine-2-carboxylate, inhibits NO in RAW264.7 and BV2 cells stimulated with LPS, with IC50 values of 115.67 and 118.80 μM, correspondingly[1].
6.25–200 μM of methyl 5-hydroxypyridine-2-carboxylate does not show any cytotoxic effects[1].
In vitro, methyl 5-hydroxypyridine-2-carboxylate exhibits NO inhibitory effects. This activity suggests potential anti-inflammatory properties. It is a phenolic acid that can be found in the stems of Mahonia fortune. It is used as a research chemical. |
| ln Vivo |
Methyl 5-hydroxypyridine-2-carboxylate is not a pharmacologically approved drug. It is a natural product and research compound with NO inhibitory activity. It has not been evaluated in clinical trials.
|
| Enzyme Assay |
In vitro assays for methyl 5-hydroxypyridine-2-carboxylate typically involve measuring nitric oxide (NO) production. A standard protocol involves culturing macrophages (e.g., RAW264.7 cells) and stimulating them with lipopolysaccharide (LPS) in the presence of varying concentrations of the compound (typically 1-100 µM). Nitrite accumulation in the culture medium is measured using the Griess assay.
|
| Cell Assay |
In vitro cell culture experiments with methyl 5-hydroxypyridine-2-carboxylate typically involve macrophages. Cells are cultured in appropriate media and treated with the compound at concentrations ranging from 1-100 µM for 24 hours. NO production and cell viability are measured.
|
| Animal Protocol |
In vivo animal studies with methyl 5-hydroxypyridine-2-carboxylate are not well documented. It is used primarily as a research compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of methyl 5-hydroxypyridine-2-carboxylate are not characterized, as it is not a drug substance. The compound is not intended for human exposure.
|
| Toxicity/Toxicokinetics |
Methyl 5-hydroxypyridine-2-carboxylate may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood.
|
| References | |
| Additional Infomation |
Methyl 5-hydroxypyridine-2-carboxylate is a phenolic acid found in Mahonia fortune that exhibits NO inhibitory effects in vitro. It has not undergone clinical trials and is not approved as a pharmaceutical.
|
| Molecular Formula |
C7H7NO3
|
|---|---|
| Molecular Weight |
153.14
|
| Exact Mass |
153.042
|
| CAS # |
30766-12-2
|
| PubChem CID |
4715126
|
| Appearance |
Off-white to pink solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
374.2±22.0 °C at 760 mmHg
|
| Melting Point |
193.5-195.5℃
|
| Flash Point |
180.1±22.3 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.552
|
| LogP |
0.82
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
149
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC(=O)C1=NC=C(C=C1)O
|
| InChi Key |
YYAYXDDHGPXWTA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H7NO3/c1-11-7(10)6-3-2-5(9)4-8-6/h2-4,9H,1H3
|
| Chemical Name |
methyl 5-hydroxypyridine-2-carboxylate
|
| Synonyms |
Methyl 5-hydroxypyridine-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (326.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (16.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5300 mL | 32.6499 mL | 65.2997 mL | |
| 5 mM | 1.3060 mL | 6.5300 mL | 13.0599 mL | |
| 10 mM | 0.6530 mL | 3.2650 mL | 6.5300 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
